Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
28.06. | Cogent (COGT) Up on SUMMIT Study Update Post Positive FDA Meeting | 2 | Zacks | ||
27.06. | Cogent Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
14.06. | Cogent Biosciences, Inc.: Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) | 70 | GlobeNewswire (Europe) | Patients treated with 100 mg bezuclastinib showed substantial reduction in their most severe symptoms and mast cell reactions Reductions were shown in all individual MS2D2 symptoms across domains... ► Artikel lesen | |
05.06. | Cogent Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
24.05. | Cogent Bio spikes after updating late-stage data for lead asset | 2 | Seeking Alpha | ||
23.05. | Cogent Biosciences, Inc.: Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer | 2 | GlobeNewswire (USA) | ||
23.05. | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting | 92 | GlobeNewswire (Europe) | Bezuclastinib + sunitinib combination therapy reached median progression free survival (mPFS) of 19.4-months and 33% ORR in subset of advanced GIST patients with one prior treatment Encouraging long-term... ► Artikel lesen | |
07.05. | Cogent Biosciences Inc reports results for the quarter ended in March - Earnings Summary | 1 | Reuters | ||
07.05. | Cogent Biosciences, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
07.05. | Cogent Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
09.04. | Cogent Biosciences, Inc.: Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor | 135 | GlobeNewswire (Europe) | WALTHAM, Mass. and BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
22.03. | Cogent Biosciences, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
26.02. | Cogent Biosciences, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
26.02. | Cogent Biosciences, Inc. - 10-K, Annual Report | - | SEC Filings | ||
26.02. | Cogent Biosciences GAAP EPS of -$0.63 | 2 | Seeking Alpha | ||
26.02. | Cogent Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
26.02. | Cogent Biosciences, Inc.: Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results | 229 | GlobeNewswire (Europe) | • SUMMIT Part 2 registration-directed study of bezuclastinib in NonAdvSM patients initiated and actively enrolling at 40 sites globally; once-daily 100 mg selected as RP2D; topline results expected... ► Artikel lesen | |
22.02. | Cogent Biosciences stock jumps on Phase 2 data for bezuclastinib | 3 | Seeking Alpha | ||
22.02. | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis | 221 | GlobeNewswire (Europe) | Registration-enabling SUMMIT Part 2 initiated and actively enrolling at 40 sites globally; RP2D selected at 100 mg once-daily optimized formulation based on: 51% week 12 mean change in Total Symptom... ► Artikel lesen | |
14.02. | HotStocks USA: Cogent Bio fast 45% im Plus | 4 | stock3.com |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
MORPHOSYS | 67,85 | +0,07 % | Schock-News für Morphosys Anleger vor dem Wochenende: So müssen Sie heute noch auf diese Sondermeldung reagieren! | ||
MEDIGENE | 1,135 | -1,30 % | PTA-News: Medigene AG: Medigene präsentiert auf dem ESMO-Kongress 2024 | DJ PTA-News: Medigene AG: Medigene präsentiert auf dem ESMO-Kongress 2024
Unternehmensmitteilung für den Kapitalmarkt
Planegg/Martinsried (pta/23.07.2024/11:15) - Die Medigene AG ( http://www.medigene.de... ► Artikel lesen | |
MODERNA | 111,52 | +0,13 % | Verlustreicher Tag für Moderna-Aktionäre: Aktienkurs sinkt deutlich (107,7255 €) | Zu den großen Verlierern an der Börse zählt am Mittwoch die Moderna-Aktie . Das Wertpapier verbilligt sich heute deutlich. Mit einem Minus von 3,55 Prozent gehört heute das Wertpapier von Moderna zu... ► Artikel lesen | |
VALNEVA | 3,292 | +0,12 % | Valneva-Aktie +6%: Das bringt neuen Schwung | Nach einer scharfen Korrektur am Freitag springt die Valneva-Aktie (WKN: A0MVJZ) am Montagmorgen um knapp +6% auf 3,48€. Eine bedeutende Finanzspritze sorgt für neue Impulse. Kann der Biotech-Titel... ► Artikel lesen | |
NOVAVAX | 15,736 | -0,18 % | Market Whales and Their Recent Bets on NVAX Options | ||
EPIGENOMICS | 0,650 | +3,83 % | EQS-Adhoc: Epigenomics AG: Vorläufiges Halbjahresergebnis zum 30. Juni 2024 | EQS-Ad-hoc: Epigenomics AG / Schlagwort(e): Halbjahresergebnis
Epigenomics AG: Vorläufiges Halbjahresergebnis zum 30. Juni 2024
22.07.2024 / 17:49 CET/CEST
Veröffentlichung einer Insiderinformation... ► Artikel lesen | |
CRISPR THERAPEUTICS | 52,75 | -1,40 % | Is a Beat in the Cards for CRISPR Therapeutics (CRSP) in Q2 Earnings? | ||
INOVIO PHARMACEUTICALS | 10,280 | -1,34 % | INOVIO Pharmaceuticals, Inc.: Inovio Receives Advanced Therapy Medicinal Product Certificate from European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate INO-3107 | Data reviewed complies with standards that would be used to evaluate an EU Marketing Authorization Application
PLYMOUTH MEETING, Pa., July 25, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology... ► Artikel lesen | |
SANGAMO THERAPEUTICS | 0,825 | +4,02 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Reports on Pfizer's Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate | Giroctocogene fitelparvovec trial meets primary and key secondary objectives of superiority compared to prophylaxis
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today... ► Artikel lesen | |
INFLARX | 1,417 | +1,50 % | InflaRx N.V.: InflaRx's GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS) | JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today... ► Artikel lesen | |
SCORPIUS | 0,050 | 0,00 % | Scorpius Holdings Set to Launch First cGMP Mammalian Manufacturing Campaign | ||
INTELLIA THERAPEUTICS | 24,570 | +0,70 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
VIVORYON THERAPEUTICS | 2,385 | -1,45 % | Vivoryon mit Neuausrichtung: Aktie legt weiter zu - das ist geplant | Die Aktie des früheren Alzheimer-Hoffnungsträgers Vivoryon hat zuletzt erneut zulegen können. Das deutsche Biotech-Unternehmen arbeitet derzeit an einer strategischen Neuausrichtung. Zukünftig will... ► Artikel lesen | |
EDITAS MEDICINE | 5,322 | +2,35 % | Editas Medicine, Inc.: Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress | All patients treated in the EdiTHAL trial maintained hemoglobin levels above the transfusion threshold and are transfusion-free post-renizgamglogene autogedtemcel (reni-cel) infusion Reni-cel was... ► Artikel lesen | |
VIKING THERAPEUTICS | 60,42 | -0,53 % | Adipositas-Hoffnung Viking Therapeutics: Aktie mit 24-Prozent-Kurssprung - was ist da los? | Die Aktie des US-Biotech-Unternehmens Viking Therapeutics hat am Mittwoch nach US-Börsenschluss einen kräftigen Kurssprung von 24 Prozent hinlegen können. Das Unternehmen, das insbesondere als großer... ► Artikel lesen |